ORKLY vs IBRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ORKLY · ORKLA ASA SPON ADR EACH REP 1 COM SHS CL A$10.83 ▼ 0.28%
IBRX · ImmunityBio$8.64 ▲ 7.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ORKLY +13.7%
- IBRX +299.8%
Head to head
| Metric | ORKLY | IBRX |
|---|---|---|
| Price | $10.83 | $8.64 |
| Change today | ▼ 0.28% | ▲ 7.80% |
| Market cap | $9.15B | $9.15B |
| Return, 3 months | -2.0% | +15.3% |
| Return, year to date | +1.4% | +336.1% |
| Return, 1 year | +13.9% | +305.4% |
| P/E (TTM) | 16.2 | – |
| P/B | 2.3 | -8.7 |
| P/E percentile vs own 5y | – | 12th |
| Dividend yield | 5.97% | – |
| Revenue growth (YoY, latest qtr) | – | +93.9% |
| Net profit growth (YoY) | – | -148.9% |
| Gross margin | – | 99.3% |
| Operating margin | – | -151.9% |
| Net margin | – | -598.6% |
| Return on equity | – | – |
| Analyst target vs. price | – | +65.0% |
| Analyst buy share | – | 100% |
| RSI (14) | 72 | 49 |
| 30-day volatility | 15.7% | 87.7% |
| Max drawdown, 1 year | -28.1% | -42.3% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IBRX is the largest of the group by market value.
- IBRX has returned the most over the past year.
- ORKLY has been the calmest stock over the last 30 days.